Nutriband Inc. (NASDAQ: NTRB) Triggers 17 Bullish Signals on Approx 42% Overnight Move

*Sponsored by Nutriband Inc. Krypton Street Announces Nutriband Inc. (NASDAQ: NTRB) As Its Next Potential Breakout Idea For Wednesday 1/22/2025. Nutriband Inc. (NASDAQ: NTRB) Comes Backed By Several  Potential Catalysts Like: Low Float With fewer than 5.1M shares in the float, Nutriband Inc. (NASDAQ: NTRB) could see significant move potential if demand begins to shift. Market Recognition: In 2024, (NTRB) moved approximately 314% in less than four months, showing its potential for significant momentum. Technical Indicators: Currently trending above its 5-day moving average, which could suggest additional upside potential. Higher Growth Potential: With a market cap under $50M, Nutriband Inc. (NASDAQ: NTRB) has the room to scale faster than larger peers. Upcoming Meeting: This week, on January 23, 2025, the Annual Meeting will address key leadership and strategy decisions shaping the company’s next phase. Game-Changing Innovation: AVERSA™ Fent-a-nyl, Nutriband’s flagship product, is setting the bar for abuse-deterrent technology with regulatory  progress underway. Global Reach: With patents in 46 countries and fresh U.S. trademark approvals, Nutriband Inc. (NASDAQ: NTRB) is securing its international presence. Keep reading to see why Nutriband Inc. (NASDAQ: NTRB) is topping our watchlist this morning… January 22, 2025 Dear Reader, When a seasoned analyst sets a bold target, you pay attention.  According to TipRanks, Noble Capital’s Robert LeBoyer just initiated coverage on Nutriband Inc. (NASDAQ: NTRB) with a bullish rating and a $13 target, which suggests over 97% in upside potential from today’s $6.59 open. Why, might you ask?  Nutriband Inc. (NASDAQ: NTRB)’s Phase 1 clinical trial for its innovative abuse-deterrent technology. According to Noble Capital, the trial is expected to pave the way for a new dr-ug application filing by the second half of 2025, with potential approval following in 2026. With milestones like these on the horizon, Nutriband Inc. (NASDAQ: NTRB) is proving it’s a name worth keeping in focus. Please tell me you have Nutriband Inc. (NASDAQ: NTRB) on your screen right now… As of this morning, Nutriband Inc. (NASDAQ: NTRB) is triggering 17 Bullish Signals on TradingView’s technical analysis tool using the 1 hour time-frame. Nutriband Inc. (NASDAQ: NTRB) opened at $6.59, reached $7.45, indicating an approximate 42% overnight move from yesterday's $5.21 close. If you missed my coverage from earlier this morning, keep reading to get up to speed. Let’s face it—there aren’t many companies in the pharmaceutical innovation space quite like Nutriband Inc. (NASDAQ: NTRB).  While others stick to tired formulas and incremental changes, Nutriband Inc. (NASDAQ: NTRB) is establishing itself as a leader in the development of advanced transdermal technologies, addressing some of the most critical challenges in healthcare today. With a low float, of less than 5.1M shares listed, we’re keeping a close eye on Nutriband Inc. (NASDAQ: NTRB) because this scarcity could lead to the potential for significant swings if demand begins to change. Nutriband Inc. (NASDAQ: NTRB) currently has a cap under $50M, which is important because companies this small have greater growth potential than large-cap companies due to their smaller revenue bases and agility. In fact, Nutriband Inc. (NASDAQ: NTRB) is #1 on our watchlist this morning… It’s important to note, Nutriband Inc. (NASDAQ: NTRB) will hold its Annual Meeting (this week) on January 23, 2025, where key decisions shaping the company’s future will be made.  The agenda includes electing directors, approving the company’s independent auditor, voting on executive compensation policies, and adopting the 2024 Amended and Restated St-ock Option Plan. Their 2024 achievements weren’t just significant; they were groundbreaking Nutriband Inc. (NASDAQ: NTRB) moved approximately 314% in less than four months from $2.22 on 3/15/2024 to $9.20 on 7/25/2024. In a year when many companies struggled to maintain relevance, Nutriband Inc. (NASDAQ: NTRB) doubled down, fortified its position, and delivered results that speak for themselves.  And if you think 2024 was big, wait until you see what 2025 has in store. Trailblazing with AVERSA™ Fent-a-nyl Nutriband Inc. (NASDAQ: NTRB)’s crown jewel, AVERSA™ Fent-a-nyl, has redefined what’s possible in abuse-deterrent therapeutics.  This groundbreaking transdermal patch is designed not just to combat misuse but to revolutionize patient safety across the board.  With support from Kindeva Dr-ug Delivery, Nutriband Inc. (NASDAQ: NTRB) made significant headway in 2024: Completed pivotal validation studies, advancing the product closer to market readiness. Established a clear regulatory path for its New Application (NDA) submission in 2025, relying on a streamlined single Phase 1 Human Abuse Potential study. This isn’t just a pipe dream, either. If approved, AVERSA™ Fent-a-nyl is projected to rake in U.S. sales of $80M to $200M annually—a staggering testament to its market potential. Global Intellectual Property Domination Nutriband Inc. (NASDAQ: NTRB) isn’t just thinking local; they’re playing on a global stage. With patent approvals in China and Hong Kong, the company now boasts intellectual property coverage in 46 countries.  A U.S. Notice of Allowance for the AVERSA™ trademark further solidified their footing, giving competitors a clear signal: Nutriband Inc. (NASDAQ: NTRB) is here to lead. Strategic Fiscal Growth Numbers don’t lie. Nutriband reported record-breaking revenues in 2024, with their contract manufacturing arm, Pocono Pharma, leading the charge: A Q3 revenue of over $645k, representing a 51% year-over-year increase. Strengthened financial reserves, courtesy of $8.4M in fresh capital from a private placement. This fiscal foundation gives Nutriband Inc. (NASDAQ: NTRB) the firepower it needs to push AVERSA™ Fent-a-nyl over the finish line while continuing to innovate. Nutriband Inc. (NASDAQ: NTRB)’s 2025 Vision: Regulatory Milestones and Global Expansion Regulatory Milestones Await: The centerpiece of Nutriband Inc. (NASDAQ: NTRB)’s 2025 ambitions is the NDA submission for AVERSA™ Fent-a-nyl. With pivotal data in hand and no need for extended Phase 2 or Phase 3 trials, the company anticipates an expedited review process.  Translation? AVERSA™ Fent-a-nyl could be on the market before the year is out. Scaling for Success: Preparation for commercialization is already underway. Nutriband Inc. (NASDAQ: NTRB) is scaling its partnership with Kindeva Dr-ug Delivery to ensure manufacturing excellence.  Simultaneously, the company is laying the groundwork for international licensing and distribution agreements, proving that they aren’t content with U.S. dominance—they’re going global. A Pipeline with Potential: AVERSA™ Fent-a-nyl is just the beginning. Nutriband Inc. (NASDAQ: NTRB) is also advancing AVERSA™ Buprenorphine and exploring additional transdermal applications. If these developments live up to their promise, Nutriband Inc. (NASDAQ: NTRB) could unlock an entirely new revenue stream, with AVERSA™ Buprenorphine alone estimated to generate $130M annually. Beyond AVERSA™: Diversification and Innovation Nutriband Inc. (NASDAQ: NTRB) isn’t putting all its eggs in one basket. The company’s manufacturing arms—Pocono Pharma and Active Intelligence—are firing on all cylinders: Expanded partnerships with retail giants like Target, Walmart, Walgreens, and CVS. Delivered innovative kinesiology and consumer health products, including an exclusive supplier agreement with Fit For Life Group, which represents Adidas, Reebok, and New Balance. Launched a Mosquito Repellent Patch in Costa Rica, marking their entry into the lucrative Central and South American markets. Why It Matters Let’s not mince words: the opioid crisis remains one of the most devastating public health challenges of our time. Nutriband Inc. (NASDAQ: NTRB) isn’t just talking about solutions; they’re delivering them. The AVERSA™ technology represents a paradigm shift in patient safety, offering a tangible way to reduce misuse, accidental exposure, and diversion of high-risk therapeutics. As CEO Gareth Sheridan aptly put it, Nutriband Inc. (NASDAQ: NTRB) is “on the brink of a transformative period in its history.”  And he’s not wrong.  The company has not only set the stage for regulatory and commercial success but also laid a solid foundation for long-term growth. The Bottom Line Nutriband Inc. (NASDAQ: NTRB) isn’t just playing in the big leagues—it’s rewriting the rulebook. With AVERSA™ Fent-a-nyl on the cusp of commercialization, an ever-expanding pipeline, and strong fiscal performance, the company is positioning itself to drive innovation and make a real-world impact in healthcare. For those watching from the sidelines, here’s your wake-up call.  Nutriband Inc. (NASDAQ: NTRB) is not just about innovation; it’s about making a meaningful impact. See Nutriband Inc. (NASDAQ: NTRB)’s corporate presentation here. 7 Reasons Why Nutriband Inc. (NASDAQ: NTRB) is #1 On Our Watchlist This Morning… 1. Low Float: Nutriband Inc. (NASDAQ: NTRB)’s low float of under 5.1M shares could set the stage for significant swing potential if demand begins to change. 2. Market Recognition: Moved approximately 314% in less than four months in 2024, displaying its potential for significant movement. 3. Technical Indicators: Nutriband Inc. (NASDAQ: NTRB) is currently trending above its 5-day moving average, which could suggest the additional momentum potential. 4. Higher Growth Potential: Nutriband Inc. (NASDAQ: NTRB) currently has a market cap under $50M, offering the potential for higher growth compared to large-cap companies due to its smaller revenue base and operational flexibility. 5. Upcoming Annual Meeting: This week, on January 23, 2025, critical decisions on leadership, strategy, and policies will shape Nutriband Inc. (NASDAQ: NTRB)’s future direction. 6. Innovating with AVERSA™ Fent-a-nyl: Nutriband Inc. (NASDAQ: NTRB)’s flagship product is setting new standards in abuse-deterrent technology with regulatory milestones approaching. 7. Global Intellectual Property Strength: With patents in 46 countries and recent U.S. trademark approvals, Nutriband Inc. (NASDAQ: NTRB) is positioned for international impact. Consider Adding Nutriband Inc. (NASDAQ: NTRB) to Your  Radar This Week… When it comes to companies redefining the game, Nutriband Inc. (NASDAQ: NTRB) stands out as a contender worth watching. With a low float under 5.1M shares, this is the kind of company that could see significant swings if demand shifts. And let’s not overlook its approximate 314% move in just four months last year—a clear demonstration of its momentum potential. Currently trending above its 5-day moving average, Nutriband Inc. (NASDAQ: NTRB) continues to show technical strength, while its market cap under $50M underscores its flexibility and room for growth compared to larger, slower-moving companies. This week’s January 23, 2025 Annual Meeting could mark a turning point, with critical decisions on leadership and strategy shaping the company’s next chapter. At the center of it all is AVERSA™ Fentanyl, a groundbreaking innovation in abuse-deterrent therapeutics that’s setting new standards for safety. With patents spanning 46 countries, Nutriband Inc. (NASDAQ: NTRB) is building a global footprint to match its ambitions. If momentum, innovation, and future potential are on your radar, Nutriband Inc. (NASDAQ: NTRB) is a name to keep in focus. Nutriband Inc. (NASDAQ: NTRB) reached $6.3643 in the pre-market, indicating an approximate 42% move from yesterday’s $5.21 close and approximately 60% from yesterday’s open.  I’ll check back in with you shortly. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KryptonStreet is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of Media 1717 LLC owns and operates kryptonstreet . com (“KS”). From time to time, KS will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: kryptonstreet.com/disclaimer/ *Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 01/21/2025 and ending on 01/22/2025 to publicly disseminate information about (NTRB:US) via digital communications. Under this agreement, Media 1717 LLC has been paid an seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from Nutriband Inc., the issuer of (NTRB:US). Neither Media 1717 LLC, TD Media LLC and their member own shares of (NTRB:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/ntrb/

Media 1717 LLC | 6586 W Atlantic Ave Unit #2086 | Delray Beach, FL 33446 US Unsubscribe | Update Profile | Constant Contact Data Notice